The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2023 | The role of Erwinia asparaginase in the treatment of ALL
Leiah Brigitha, Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands, briefly discusses the role of Erwinia asparaginase in the treatment of acute lymphoblastic leukemia (ALL). PEG-asparaginase is commonly used in first-line ALL treatment as it is more convenient due to a lower frequency of administration, however Erwinia asparaginase is a good alternative in these patients if PEG-asparaginase treatment must be discontinued or is not available for any reason. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Speaker fee: Servier, Clinigen
